Acharya Tulsi Regional Cancer Treatment & Research Institute
Acharya Tulsi Regional Cancer Treatment & Research Institute,
(Regional Cancer Centre)
S.P. Medical College & Associated Group of Hospitals,
Bikaner 334 003 (Rajasthan)
Treatment of cancer patients in Bikaner has a very old and distinguished history. Even earlier than 1940, in the whole North-West India, Bikaner was the only place to provide Radiation Therapy by the deep and superficial X-ray to cancer patients. In pre- independent era, cancer treatment by Radium was made available here. The first Tele-Cobalt-60 machine for treatment of cancer patients was commissioned in 1965. Thereby keeping pace with the developments in the treatment of cancer around the world, Bikaner had become one of the oldest and prime centres of treatment of cancer in North-West part of India.
Since 1994, and afterwards, persistent efforts were made by public, philanthropic organizations, local administration and Government of Rajasthan, in order to get S.P. Medical College and A.G. of Hospitals, Bikaner, recognized as a Regional Cancer Centre (R.C.C.). Due to these efforts, the Government of India accorded the status of 13th Regional Cancer Centre to Sardar Patel Medical College, Bikaner on 19th July 1999.
The Acharya Tulsi Regional Cancer Treatment and Research Institute (Regional Cancer Centre) Bikaner is the 13th Regional Cancer Centre in India, is situated at Bikaner (Rajasthan) and is a Registered Society under Rajasthan Society Registration Act. 1958 (Rajasthan Act No. 28, 1958) w.e.f. 13th March 2000. The Registration No. issued by the Registrar, Co-operative Societies, Bikaner is 139/99-2000.
The buildings of the Institute have been constructed by the Acharya Tulsi Shanti Pratisthan Bikaner and were donated for its use. The staff and doctors are arranged by the Govt. of Rajasthan. Various equipments have been procured from the aid of Central Government for better treatment of cancer patients.
GOVERNING BOARD MEMBERS
ACHARYA TULSI REGIONAL CANCER TREATMENT & RESEARCH INSTITUTE
(REGIONAL CANCER CENTRE)
S.P. MEDICAL COLLEGE & A.G. OF HOSPITALS, BIKANER (RAJ.)
1 |
|
Chairman |
2 |
Principal Secretary to the Govt. of Rajasthan Medical Education Dept. Jaipur |
Vice-Chairman |
3 |
Principal Secretary to the Govt. of Rajasthan, Department of Finance, Jaipur |
Member |
4 |
Dy. Secretary to the Govt. of India Ministry of Health & Family Welfare Department (Cancer Desk) New Delhi |
Member |
5 |
Dy. Director, Health & Family Welfare, Govt. of India, New Delhi |
Member |
6 |
Dr. G.K. Rath, Professor & Head, IRCH, AIIMS, New Delhi |
Founder Member |
7 |
Dr. S.C. Lodha, Retired Principal, Jaipur |
Member |
8 |
Dr. B.D. Kalla, Eminent Citizen & Ex-Minister |
Member |
9. |
Dr. Raja Babu Panwar, Vice Chancellor, RUHS, Jaipur |
Special Member |
10 |
Dr. Vinod Bihani Controller of Examiner, R.U.H.S., Jaipur |
Special Member |
11 |
Dr. R.P.Agarwal Principal S.P. Medical College, Bikaner |
Member |
12 |
Dr. P.K. Berwal Suptd. P.B.M. Hospital, Bikaner |
Member |
13. |
Dr. H.S.Kumar Professor & Head, Dept. of Radiotherapy |
Member |
14 |
Sh. Jethmal BOthra, Businessman Bikaner |
Founder Member |
15 |
Sh. Subhu Patwa, Social Worker, Bikaner |
Founder Member |
16. |
Sh. Ajay Chopara, Bikaner |
Member |
17 |
Sh. Sohan Lal Baid, CA, Bikaner |
Member |
18 |
Sh. Sumer Mal Daftri, Bikaner |
Honorary Member |
19 |
Sh. Nand Kishore Mohta, Businessman, Bikaner |
Honorary Member |
20 |
Sh. Shiv Ratan Agarwal, Social Worker, Bikaner |
Donor Member |
21 |
Sh. Monohar Lal Agarwal, New Delhi |
Donor Member |
22 |
Sh. Mool Chand Daga, Social Worker, Bikaner |
Donor Member |
23 |
Sh. Rakesh S. Kathotia, Mumbai |
Donor Member |
24 |
Sh. Prem Chand Golia, Mumbai |
Donor Member |
25 |
Sh. Hukum Chand Bothra, Bikaner |
Donor Member |
26 |
Dr. M.R. Bardia Director, Acharya Tulsi Regional Cancer Treatment & Research Institute, Bikaner |
Member Secretary |
INFRASTRUCTURES:
Buildings:
1. Main Buildings of the Institute: The O.P.D. all diagnostic, C.T. Simulator and therapy facilities, administrative office, cash counter, registration counter and Doctors chamber are located under one roof. This minimizes the problems of patients to move to different places. In order to manage mental tension, worry and depression a Meditation Room has been provided in the Institute. This Meditation facility is named as “Acharya Mahapragya Dhyan Kaksh (Room)” in reverence to the present Acharya and Dharma Guru of “Terapanth” Acharya Maha Pragya Ji. This room is also used for holding Classes, Journal Club, Seminars, Symposium, training and conferences.
2. New Cancer Ward : A new double storied cancer ward with 50 beds has been constructed in the year 2002.
3. Additional Cancer Ward: Another 120 bedded cancer ward has been constructed.
4. Cancer Cottage Ward: 23 Cancer Cottage Wards “Preksha Cottage”.
5. Cobalt-60 Room.
6. Yatri Vishram Grah: For the accommodation of patients and relatives Yatri Vishram Grah was constructed.
7. The Surgical Oncology Wing: This wing consists of Operation Theatres, Post Operative Ward and Surgical Oncology Wards etc.
8. Room for Linear Accelerator: The room for Linear Accelerator Machine has been constructed.
9. Palliative Care Unit Building
10. TCCC Project: Under TCCC project Bone Marrow Transplant Unit, 2 Linear Accelerator and One Brachytherapy machine to be installed.
11. Bone Marrow Transplant Unit: Construction work is going on.
Equipments:
Availability of essential diagnostic and treatment facilities under one roof is of crucial importance for prompt commencement of treatment and subsequent monitoring besides being a big relief to cancer patients. This policy is always kept in view, in the process of developmental activities of this centre. The equipments available in this institute are as under:-
1. High Dose Rate (HDR) Brachytherapy Machine
2. Three Tele Cobalt Radiotherapy Machine (780-E) , (780-C) & Bhabhatron-II
3. The Dual Head Variable Angle Gamma Camera with SPECT.
4. Multimodality High Energy Linear Accelerator
5. Ultrasonography Machine.
6. 500 mA X-Ray Machine.
7. Blood Cell counters Machine.
8. Semi Auto Analyser (Biochemistry)
9. 3-D T.P.S. Machine.
10. Radiotherapy C.T. Simulator
11. Electric Generator
Academic Activities:
Teaching:
1. Once a week seminar presented by postgraduate students and attended by all faculty members.
2. Once a week Journal’s club presented by faculty members and attended by all postgraduates students. In this meeting recent advances in oncology, allied branches and related basic sciences are discussed.
3. For Postgraduate students, weekly clinical meetings of case presentation are held. In this event academically informative patients are discussed in detail. Clinical classes for under graduate students are held as per teaching schedule of the college.
4. Theory lectures for postgraduate and under graduate students are regularly held as per teaching schedule of the Institute and college.
5. Monthly Medical College level clinical academic meeting is held, which is attended by all faculty members and postgraduate students. The cancer institute participates actively in these clinical meetings.
6. Tumor Board meeting once a week-participation by surgical, radiotherapy, ENT & Pathology department of S.P. Medical College, Bikaner
Research:
(A) Regular research work is carried out on various projects, the details of which are as under:
Research Projects:
1. National Tumor Registry Programme- I.C.M.R. Project.
2. W.H.O. Population Screening Programme for Cancer of Cervix, Breast & Oral Cavity.
3. Role of Amiphostine as Radio-Chemo Protective during Cancer Treatment.
4. Role of Carboplatin as Radiation sensitizer in Head and Neck Cancer Patients.
5. External Radiotherapy, Brachytherapy and adjuvant chemotherapy in the malignancy of Oesophagus.
6. Use of Newer chemotherapy agent (Paclitexil) in Head and Neck Cancer treatment with radiotherapy.
7. Project of WHO on Cancer Pain assessment and palliative care.
8. Study of role of Serum, Zinc, Magnesium & Molybdenum in Cancer Oesophagus.
9. Breast conservation using Chemotherapy, External Beam Radiotherapy and Brachytherapy.
10. Facility of Radiation Exposure is made available to the Radiobiology research scholars, scientists and faculty members of postgraduate science college, University of Bikaner.
(B) Academic Paper presentation and participation in conferences /workshops.
(i) Faculty members attend National, International conference and workshops of Radiotherapy, Radiation Physics, Nuclear Medicine/Radiation Medicine, in the country. Postgraduate students are encouraged to attend the conference and present their research work.
(ii) Our faculty members and P.G. Students presented research papers in National Conferences which were related to “CHART” way of Radiotherapy, Radio necrosis of face bones in Head & Neck Cancer Radiotherapy, unusual sites of metastasis, HDR in the malignancy of Oesophagus, Spleenic irradiation in CML and Bone Metastasis in CML patients.
(iii) Our P.G. Students attended teaching programme and workshops arranged for P.G. students at PGI Chandigarh and Ahemdabad in last 2 years.
(C) Global Clinical Research Project/Trials
Clinical Trials Completed:
1. IL-2 Clinical Trial: A multi-centric, open label, phase III clinical trial to evaluate the safety and efficacy of Interleukin- 2 (Zenotech) in patients with metastatic renal cell carcinoma, followed up to 6 months for survival. (Study Number: Zen-03/2004) The Clinical Trial sponsored by M/s Credence Clinical Research Pvt. Ltd.,,Hyderabad has also been taken up by our Institute. It would help the Cancer patients for their better treatment.
2 BC-0601 Clinical Trial -Efficacy of the blood based gene expression test for Breast Cancer in an Indian population in women with and without breast cancer in various geographical locations.: The Clinical Trial sponsored by M/s Manipal Acunova Ltd.,Bangalore has also been taken up by our Institute.
3 A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trail of the Efficacy and Safety of APF-530 compared to Aloxi for the prevention of Acute-onset and Delayed-Onset Chemotherapy-induced nausea and vomiting following the administration of either moderately or highly emetogenic chemotherapy regimens: The Clinical Trial sponsored by M/s Neeman Medical International Asia Ltd., New Delhi
4 A study of Mycobacterium w in combination with paclitaxel plus cisplatin in Advanced NSCLC: This Clinical Trial also sponsored by M/s Cadila Pharmaceuticals Ltd. Ahmedabad.
5 A Phase III Randomized, Double Blind, Placebo-controlled study to access the efficacy and safety of 10mg ZD4054 in combination with Docetaxel in comparison with Docetaxel in patients with metastatic Hormone resistant Prostate Cancer: The Clinical Trial sponsored by M/s ICON Clinical Research India Pvt. Ltd. Bangalore.
6 A Phase III Randomized, Double Blind study to Assess the efficacy and safety of 10mg ZD4054 versus Pacebo in patients with Hormone Resistant Prostate Cancer and Bone Metastasis who are pain free or mildly symptomatic.: This Clinical Trial also sponsored by M/s ICON Clinical Research India Pvt. Ltd. Bangalore.
7 A Randomized Phase-III-b Multicentre, Open label, parallel study of Enoxaparin (low molecular weight heparin) given concomitantly with chemotherapy in patients with inoperable gastric cancer (Gastranox):
This Clinical Trial sponsored by M/s Criterium Clinical Research India Pvt. Ltd. Pune.
8 “Prospective, multi-centre, randomized, open-label, two-arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-016/ Herceptin® (HerclonTM) when given intravenously in patients with Metastatic HER2- Overexpressing Breast Cancer” PI: Dr.M.R.Bardia
9 Protocol No. HCR/III/Ritux/06/2012 “A randomized, multiple-dose, multicentre, comparative parallel study to evaluate the Efficacy, Safety and Pharmacokinetic characteristics of Intravenous Infusion of Rituximab (Hetero) And Reference Medicinal Product (Rituximab, Roche) in Indian patients of Non-Hodgkin's Lymphoma (HERILY Study)” PI: Dr.Surender Beniwal
10 “Prospective, multi-centric, open-label, two-arm, parallel group, active-control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-017 / MabThera®(Ristova®) in patients with Non-Hodgkin's Lymphoma”
11 “Prospective, multi-centre, randomized, open-label, two arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-023/ Avastin™ when given intravenously in patients with Metastatic colorectal cancer” PI: Dr.M.R.Bardia
12 Study Title: “LUX- Head & Neck 2: A randomized, double blind, placebo- controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.” PI: Dr. Ajay Kumar Sharma
13 “A prospective, randomized, multi-centric clinical study to compare Trastuzumab (Test Product, Zydus) with Trastuzumab (Reference Product, Roche/Genentech) in patients with metastatic breast cancer”.PI: Dr. Ajay Kumar Sharma
14 Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-029/ Neulasta® (Neulastim®) when given subcutaneously in patients with Chemotherapy Induced Neutropenia” PI: Dr. Ajay Kumar Sharma
15 Study Title: A double blind, multicentric, randomized controlled clinical trial to evaluate the efficacy and safety of VRP-1620 in increasing the sensitivity of sonomammography and lateral chest x-ray in patients of breast cancer PI: Dr.Neeti Sharma
16 Protocol title: Phase II Clinical Trial of Immunotherapy with an Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine in Patients with Stages IIIB/IV Non-Small Cell Lung Cancer That Have Completed First Line Chemotherapy. PI: Dr.Shankar Lal Jakhar
17 A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy PI: Dr.Surender Beniwal
18 Protocol Title: “A multicenter open-label randomized study of BCD-020 (rituximab, CJSC BIOCAD, Russia) efficacy and safety in comparison with MabThera® / Ristova® (F. Hoffmann-La Roche Ltd., Switzerland) in monotherapy of CD20-positive indolent non-Hodgkin lymphoma”. (Folicular lymphoma)
19 Phase III clinical trial comparing safety and efficacy of BCD022 (CJSC BIOCAD, Russia) used with paclitaxel to Herceptin® used with paclitaxel in the firstline treatment of HER2 positive metastatic breast cancer patients. (HER2 positive metastatic naïve cases)
Ongoing Clinical Trials/Projects
1 “A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, Phase 3 study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit” PI: Dr.Shankar Lal Jakhar
2 Protocol Title: A Phase II, Multicenter, Randomized, open Label, and Parallel Group Study to Evaluate Efficacy and Safety of endoxifen as First-Line Therapy in Women with Metastatic Estrogen Receptor Positive Breast Cancer (metastatic breast cancer naïve cases)
Ongoing PI Name: Dr Shankar Lal Jakhar
3 Project # MYL-1402O-3001 :Multicentre, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First -line treatment of Patient with Stage IV Non-Squamous Non-Small Cell Lung Cancer
4 A randomised double-blind study in two parts Part A - Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC) and Part B - Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC) Ongoing
5 [AB12003] A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC). Ongoing
Early Detection and Cancer Awareness Programme
Govt. of India has designate our Institute as Nodal agency to conduct District Cancer Control Programme under National Cancer Control Programme for the Naguar and Bikaner Districts and adjoining districts.
ACHARYA TULSI REGIONAL CANCER TREATMENT AND RESEARCH INSTITUTE
S.P. MEDICAL COLLEGE & ASSOCIATED GROUP OF HOSPITALS,
BIKANER (RAJASTHAN)
(REGIONAL CANCER CENTRE)
GENERAL STATISTICS OF REGISTERED CANCER CASES
A. Number of Cancer Patients reported in Radiation Oncology Outdoor.
Year |
New Cases (A1) |
Follow-up Cases (A2) |
2001 |
5129 |
35768 |
2002 |
5552 |
38582 |
2003 |
5446 |
38263 |
2004 |
5686 |
38341 |
2005 |
6115 |
43833 |
2006 |
5708 |
50562 |
2007 |
6516 |
51676 |
2008 |
6236 |
49402 |
2009 |
6138 |
45357 |
2010 |
6295 |
45189 |
2011 |
5787 |
43189 |
2012 |
6983 |
47640 |
2013 |
7543 |
56728 |
2014 |
8591 |
66330 |
2015 |
10064 |
79198 |
2016 |
10080 |
83438 |
B. Number of Cancer Patients admitted in Cancer Ward.
S.No. |
Year |
Numbers |
1 |
2001 |
10783 |
2 |
2002 |
11531 |
3 |
2003 |
13024 |
4 |
2004 |
13611 |
5 |
2005 |
16744 |
6 |
2006 |
17392 |
7 |
2007 |
16324 |
8 |
2008 |
17063 |
9 |
2009 |
12244 |
10 |
2010 |
13689 |
11 |
2011 |
10016 |
12 |
2012 |
11471 |
13 |
2013 |
13742 |
14 |
2014 |
14496 |
15 |
2015 |
18148 |
16 |
2016 |
15323 |
C. Number of Cancer Patients treated on Theratron-60, Theratron-780-C and Theratron-780-E.
S.No. |
Year |
Number |
Machine |
1 |
2001 |
2034 |
Theratron-780 C + Theratron 780-E (April 2001) |
2 |
2002 |
2125 |
Theratron-780 C + Theratron 780-E |
3 |
2003 |
2345 |
Theratron-780 C + Theratron 780-E |
4 |
2004 |
2840 |
Theratron-780 C + Theratron 780-E |
5 |
2005 |
2582 |
Theratron-780 C + Theratron 780-E |
6 |
2006 |
2468 |
Theratron-780 C + Theratron 780-E |
7 |
2007 |
2683 |
Theratron-780 C + Theratron 780-E |
8 |
2008 |
2245 |
Theratron-780 C + Theratron 780-E |
9 |
2009 |
2821 |
Theratron-780 C + Theratron 780-E |
10 |
2010 |
3103 |
Theratron-780 C + Theratron 780-E |
11 |
2011 |
2887 |
Theratron-780 C + Theratron 780-E |
12 |
2012 |
2527 |
Theratron-780 C + Theratron 780-E |
13 |
2013 |
2575 |
Theratron-780 C + Theratron 780-E |
14 |
2014 |
2506 |
Theratron-780 C + Theratron 780-E+ Bhabhatron-II |
15 |
2015 |
2693 |
Theratron-780 C + Theratron 780-E+ Bhabhatron-II |
16 |
2016 |
2635 |
Theratron-780 C + Theratron 780-E+ Bhabhatron-II |
D. Number of Cancer Patients who received Brachytherapy
S.No. |
Year |
Number |
1 |
2001 |
371 |
2 |
2002 |
362 |
3 |
2003 |
385 |
4 |
2004 |
361 |
5 |
2005 |
390 |
6 |
2006 |
373 |
7 |
2007 |
396 |
8 |
2008 |
446 |
9 |
2009 |
413 |
10 |
2010 |
463 |
11 |
2011 |
418 |
12 |
2012 |
339 |
13. |
2013 |
263 |
14. |
2014 |
0 |
15 |
2015 |
0 |
16 |
2016 |
0 |
E. Number of Cancer Patients examined by Gamma Camera
S.No. |
Year |
Number |
1 |
2002 |
309 |
2 |
2003 |
736 |
3 |
2004 |
771 |
4 |
2005 |
807 |
5 |
2006 |
918 |
6 |
2007 |
1213 |
7 |
2008 |
961 |
8 |
2009 |
721 |
9 |
2010 |
642 |
10 |
2011 |
715 |
11 |
2012 |
836 |
12 |
2013 |
773 |
13. |
2014 |
0 |
14 |
2015 |
0 |
15 |
2016 |
0 |
F. Number of Cancer Patients who received treatment on Linear Accelerator
S.No. |
Year |
Number |
1 |
2008 |
140 |
2 |
2009 |
105 |
3 |
2010 |
143 |
4 |
2011 |
187 |
5 |
2012 |
341 |
6 |
2013 |
233 |
7. |
2014 |
300 |
8. |
2015 |
408 |
9 |
2016 |
322 |
Details of Surgery
S.No. |
Year |
Major Surgery |
Minor Surgery |
Bronchoscopy |
Total |
1 |
2012 |
142 |
472 |
467 |
1081 |
2. |
2013 |
187 |
348 |
739 |
1274 |
3. |
2014
|
285 |
316 |
968 |
1569 |
4 |
2015 |
304 |
274 |
777 |
1355 |
5 |
2016 |
286 |
251 |
1006 |
1543 |